Aims-To investigate the immunoreactivity of a range of melanocytic lesions, both benign and malignant, with the monoclonal antibody VS38. This was recently described as a marker ofreactive/ neoplastic plasma cells and, therefore, is useful in the diagnosis of plasmacytomal myeloma and lymphomas with plasmacytic differentiation. This study was prompted by the recent observation that a plasmacytoid melanoma arising in the nasal cavity was strongly inumunoreactive with VS38, which was therefore a potential source of major diagnostic error. Methods-The Streptavidin-peroxidase complex technique was used on paraffin wax embedded sections of 167 melanocytic lesions. Diaminobenzidine (DAB) was used as chromogen for non-pigmented or lightly pigmented lesions and nickel/DAB for more heavily pigmented lesions. Results-Positive immunostaining for VS38 was seen in 14'5% (10/69) of benign naevi (including 40% (four of 10) of Spitz naevi), 10-5% (two of 19) of dysplastic naevilin situ melanomas, 92% (35/38) of primary cutaneous melanomas, 100% (four of four) of primary mucosal melanomas, 91-7% (33/36) of recurrent/metastatic melanomas, and 100% (one of one) of clear cell sarcomas of soft tissues.
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Methods
The spectrum of melanocytic lesions studied is shown in table 1. They constituted a random selection of cases from within specified SNOMED coded groups which had been biopsied between 1992 and 1995. Lesions had been removed from patients over a wide age range and one was a malignant melanoma from a child. Primary cutaneous malignant melanomas ranged from 0 3 to 9 5 mm in Breslow depth. The metastatic melanomas were within lymph nodes with the exception of two cases, one of which was in skeletal muscle and the other within subcutaneous tissue. All of the recurrent melanomas were in dermis and/or subcutaneous tissue with the exception of one case which recurred as neurotropic melanoma growing along the radial nerve. 
Discussion
In 1994 Turley et al' established that the monoclonal antibody VS38 recognises both normal and neoplastic plasma cells through affinity for a 64 kilodalton intracytoplasmic antigen. These workers tested VS38 reactivity in histological sections from a range of normal tissues which had been pretreated in a microwave oven. No immunoreactivity could be established without microwave pretreatment. In addition to plasma cells, they noted positivity in tonsillar epithelium, exocrine pancreas, renal distal tubules and Bowman's capsule, adrenal glomerulosa cells, and gut APUD (amine precursor uptake and decarboxylation) cells. In the brain, VS38 highlighted neurons, glial cells and Purkinje cells. Unidentifiable stromal spindle cells were also reported to be strongly positive in some tissues, a finding which we also noted in some of our cases.
VS38 reactivity was also investigated in a number of cell lines and tissue sections of selected neoplastic lesions.' Some non-plasma cell tumours such as lymphoplasmacytoid lymphomas were positive, with weak staining also in a proportion of B cell, large cell nonHodgkin's lymphomas. Weak cross-reactivity with non-neoplastic epithelium as well as with epithelial tumours was also noted,' although haematopoietic cells of lineage other than plasma cells were negative. It was shown by western blotting that a breast carcinoma cell line also contained a strong protein band of 64 kilodaltons. Although positivity for VS38 has been noted in single melanoma cell line,' ours is the first reported study of VS38 immunoreactivity in melanocytic lesions.
The present study was initiated after we found immunohistochemical positivity for VS38 in a plasmacytoid intranasal malignant melanoma. Further investigation revealed positivity of the same tumour for S-100 protein, NKI/C3 and HMB-45 and a diagnosis ofmalignant melanoma was therefore made. Reactivity for VS38 in such a situation where malignant melanoma is not initially considered on morphological grounds could potentially lead to an erroneous diagnosis. Whilst this sort ofproblem may not arise in lesions from cutaneous sites, primary melanomas at less common locations or metastatic tumours could pose problems of interpretation. This is particularly so given the notoriously chameleon-like morphology of malignant melanomas.
The classic immunophenotypic markers of melanocytic lesions are S-100 protein, NKI/C3 and HMB-45 in order of increasing specificity. NKI/C3 is more specific than S-100i but its specificity for melanocytic lesions is not absolute."A HMB-45 is the most specific marker ofmalignant melanoma, although there are rare reports of immunoreactivity in other tumours.5 Up to 13% of melanomas are negative for HMB-45 (from pooled literature data).6 Malignant melanoma may also express cytokeratins,67 neurofilament protein,7 desmin,59 oc-smooth muscle actin,6 KP1 (CD68),'°and epithelial membrane antigen (EMA)." It could be argued that VS38 expression which we found in the majority of malignant melanomas represents an extension ofthe anomalous immunophenotype of melanomas. We did not observe sufficient sequential specimens in the present study to make any valid comment on temporal alterations in VS38 immunoreactivity. The explanation for the focal nature of staining for VS38 in the lesions described is unclear although it is interesting that heterogeneity of staining of melanoma cells for HMB-45 is also well recognised. '2 Although our study has shown positivity for VS38 in a majority of malignant melanomas and in a minority of benign naevi, it should not be used as a discriminator between difficult benign and malignant melanocytic lesions. Morphological features remain paramount in this distinction in difficult cases because 40% of Spitz naevi were positive.
In conclusion, we would like to emphasise that VS38C is not entirely specific for plasmacytoma/myeloma and is particularly expressed in malignant melanoma. If an undifferentiated tumour is encountered in which VS38 positivity is seen, we recommend a panel of immunohistochemical markers which should include NKI/C3 and HMB-45 to exclude malignant melanoma, even if the tumour has a plasmacytoid appearance suggestive of myeloma/ plasmacytoma.
